Agenus | AGEN - Selling And Administration Expenses


Agenus reported $10.56M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 7.84M 1.21M Dec/2025
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.75B 831M Dec/2025
Jiangsu Hengrui CNY 3.01B 227.63M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Merck USD 2.85B 215M Dec/2025
Northwest Biotherapeutics USD 7.07M 1.06M Sep/2025
Novartis USD 3.44B 128M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 43.31M 8.43M Dec/2025